Загрузка...
Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study
Benign Prostate Hyperplasia (BPH) has been associated with prostate cancer prevalent among men after 50 years of age, however, it is unclear whether the antidiabetic drug, metformin, can reduce prostate cancer for men with BPH. The insurance claims data of men aged 50 years or older, with both type...
Сохранить в:
| Опубликовано в: : | Cancer Med |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536940/ https://ncbi.nlm.nih.gov/pubmed/30968600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2025 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|